Welcome to our dedicated page for Skinvisible SEC filings (Ticker: SKVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SKVI SEC filings page on Stock Titan is intended to provide investors with access to Skinvisible, Inc. regulatory disclosures as they become available, alongside AI-generated summaries. Skinvisible is a pharmaceutical research and development company that develops and licenses Invisicare®-based topical and transdermal formulations for dermatology, obesity and glucose-controlling indications.
Although no recent SEC filings are listed in the provided data, this page is designed to aggregate key U.S. Securities and Exchange Commission documents for SKVI when they are filed. These may include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as licensing agreements, clinical milestones or changes in the company’s operations.
For a company like Skinvisible, SEC filings can offer additional detail on its licensing arrangements, milestone and royalty structures, and the status of its Invisicare-based research programs. They may also discuss risk factors related to dependence on partners for clinical development and regulatory approvals, as well as the scope of patent applications covering transdermal delivery of GLP-1 receptor agonists, CB-1 receptor antagonists and other glucose-controlling agents.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight important sections, helping readers quickly identify information about Skinvisible’s business focus, technology strategy and material agreements. As new SKVI filings are submitted to EDGAR, this page will update to reflect the latest regulatory disclosures and provide structured access to the underlying documents.
Skinvisible, Inc. reports full-year 2025 results showing minimal revenue and continued financial strain. Revenue was $20,000, unchanged from 2024, with no cost of revenues, but operating expenses of $516,315 and a net loss of $1,064,034.
The company ended 2025 with cash of $2,620, a working capital deficit of $4,990,414, and an accumulated deficit of $41,010,176, leading auditors and management to highlight substantial doubt about its ability to continue as a going concern. Skinvisible continues to rely on licensing its Invisicare delivery technology, including its key Quoin Pharmaceuticals license for QRX003 in Netherton Syndrome, which has received multiple regulatory designations and is progressing toward a potential Phase 3 program.
Skinvisible, Inc. (SKVI) filed its Q3 2025 report, showing minimal revenue alongside ongoing losses and liquidity pressure. Revenue was $5,000 for the quarter and $15,000 year‑to‑date, unchanged year over year. The company posted a net loss of $250,245 for the quarter and $805,677 for the nine months.
Cash was $645 at September 30, 2025, against total current liabilities of $4,765,644 and total liabilities of $10,138,047, resulting in a working capital deficit of $4,737,175. Accrued interest payable was $3,212,969. Management states these conditions raise substantial doubt about continuing as a going concern. Basic loss per share was $0.05 for the quarter.
Shares outstanding were 5,403,843 as of November 13, 2025. The filing notes 82,346,405 additional shares issuable in connection with convertible notes as of September 30, 2025. Internal controls were deemed not effective due to material weaknesses. Operating expenses declined year over year, and the company highlights licensing progress with Quoin and Ovation as potential future revenue drivers.